In 2020, combination therapy with atezolizumab, an immune checkpoint inhibitor, and bevacizumab, an anti-vascular endothelial growth factor (VEGF) monoclonal antibody, demonstrated superior overall and progression-free survival compared to sorafenib and became the preferred first-line treatment for advanced HCC. The gene discussed is VEGFA; the disease is hepatocellular carcinoma.